ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lifetime health products pty ltd - propolis dry extract, quantity: 400 mg (equivalent: lead, qty 0.8 microgram; equivalent: propolis, qty 2 g) - capsule, soft - excipient ingredients: white beeswax; purified water; carob pod; lecithin; hydrogenated vegetable oil; gelatin; iron oxide red; soya oil; glycerol; iron oxide black; grape seed oil - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing ; maintain/support healthy immune system function

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lifetime health products pty ltd - vitis vinifera -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lifetime health products pty ltd - propolis dry extract -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lifetime health products pty ltd - royal jelly lyophilised, quantity: 200 mg (equivalent: 10-hydroxy-2-decenoic acid, qty 12 mg) - capsule, soft - excipient ingredients: purified water; d-alpha-tocopherol; soya oil; yellow beeswax; gelatin; lecithin; calcium carbonate; glycerol; hydrogenated vegetable oil - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lifetime health products pty ltd - green lipped mussel -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lifetime health products pty ltd - squalene, quantity: 1 g - capsule, soft - excipient ingredients: purified water; soya oil; d-alpha-tocopherol; glycerol; gelatin - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lifetime health products pty ltd - shark cartilage -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide monohydrate, quantity: 1.069 g (equivalent: cyclophosphamide monohydrate, qty 1 g) - injection, powder for - excipient ingredients: - frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter's staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *modified as the international staging classification for hodgkin's disease in 'report of the committee on the staging of hodgkin's disease'. cancer res 26: 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or waldeyer's ring. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer's ring. all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms. frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung. immunosuppressive properties: cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide monohydrate, quantity: 534.5 mg (equivalent: cyclophosphamide monohydrate, qty 500 mg) - injection, powder for - excipient ingredients: - frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter's staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *modified as the international staging classification for hodgkin's disease in 'report of the committee on the staging of hodgkin's disease'. cancer res 26: 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or waldeyer's ring. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer's ring. all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms. frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung. immunosuppressive properties: cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

lifetime health products pty ltd - honey,propolis dry extract -